Chambal Fert. Q1 FY27 Earnings Call — Analysis (NSE: CHAMBLFERT)
Chambal Fertilisers Q1 EBITDA rises 12% to ₹851 Cr, margins expand 350bps; new urea investment policy paves way for fourth plant, TAN project advances
The take
Q1FY27 Revenue from operations ₹5,000 Cr ( -12% YoY ) . New guidance — Q1FY28 imacid phosphoric acid capacity… 700,000 tons . New story: Urea policy transition and capacity expansion .
Results
Revenue from operations ₹5,000 Cr, down 12% YoY; EBITDA ₹851 Cr, up 12% YoY with margins at 17% (+350bps); PAT ₹703 Cr, up 10% YoY; complex fertilizer EBIT surged 67% to ₹239 Cr.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Revenue from operations | ₹5,000 Cr | -12% | yoy · Q1FY27 · ₹5,700 Cr in Q1FY26 |
| EBITDA | ₹851 Cr | +12% | yoy · Q1FY27 |
| EBITDA margin | 17% | +350bps | yoy · Q1FY27 · 13% in Q1FY26 |
| PAT | ₹703 Cr | +10% | yoy · Q1FY27 |
| PAT margin | 14% | +3pp | yoy · Q1FY27 · 11% in Q1FY26 |
| Urea segment revenue | ₹2,860 Cr | -8% | yoy · Q1FY27 |
| Complex fertilizer segment revenue | ₹1,737 Cr | -18% | yoy · Q1FY27 |
| Complex fertilizer segment EBIT | ₹239 Cr | +67% | yoy · Q1FY27 |
| Crop protection & specialties segment revenue | ₹430 Cr | -6% | yoy · Q1FY27 |
| Crop protection & specialties segment EBIT | ₹108 Cr | +13% | yoy · Q1FY27 |
| Subsidy received | ₹2,480 Cr | -1.3% | yoy · Q1FY27 · ₹2,512 Cr in Q1FY26 |
| Total receivables | ₹3,300 Cr | point_in_time · Q1FY27 · as of 30 June 2026 | |
| Market debtors | ₹841 Cr | point_in_time · Q1FY27 | |
| Subsidy receivables | ₹2,460 Cr | point_in_time · Q1FY27 |
Guidance
Fourth urea plant under NUP-2026 targeted for commissioning by 2030; TAN HDAN commissioning shortly and full product/marketing mix by Dec-26; complex fertilizer margins to moderate but remain healthy; NPK tie-up of 8.5 lakh tons in place.
What management committed to
- The fourth urea plant will be delivered (commissioned) within 2030. — FY31
- For the new urea plant, EBITDA per ton is expected to be around ₹12,000 per ton. — ₹12,000 per ton
- High-Density Ammonium Nitrate (HDAN) production will commence shortly. — shortly
- All product and marketing mix elements for the TAN project (including warehouses) will be completed by end of December 2026, enabling generation of target volumes and numbers. — Q3FY27
- Products from the TERI collaboration (CFCL-TERI Centre of Excellence for Advanced and Sustainable Agriculture Solutions) are expected to be launched from FY28-29 onwards. — FY29
- IMACID (joint venture) phosphoric acid capacity will be expanded from 500,000 tons to 700,000 tons and be operational by middle of next year (April-June 2027). — 700,000 tons, Q1FY28
- Chambal will maintain its dividend payout at around 25% of profits going forward. — around 25%, going forward
Key themes
New urea policy and capacity expansion
How the narrative shifted
- Urea policy transition and capacity expansion: Management positions the newly approved NUP-2026 as a game-changer, enabling a brownfield fourth urea plant at Gadepan that leverages scale, existing infrastructure, and market leadership, despite lower ROE than previous policy.
- TAN project ramp-up and product diversification: The TAN project is moving from trial to commercial phases; HDAN startup imminent and full product/marketing mix to be ready by December, allowing combination optimization. Positioned to capture growing domestic demand for explosives-grade ammonium nitrate despite potential near-term oversupply, with scale and cost advantages.
- Raw material volatility and geopolitical risk: Geopolitical tensions in West Asia disrupted ammonia, sulphur, and freight supply chains, causing sharp input cost spikes. Sulphur shortages forced IMACID shutdown; management expects normalization but acknowledges ongoing risk.
- Monsoon recovery and demand acceleration: Delayed monsoon initially depressed Kharif sowing and fertilizer offtake, but July revival closed the acreage gap. Strong farmer sales in July (urea 19-20k tons/day, NPK ~92k tons) signal a robust Q2, with channel restocking to follow.
- Complex fertilizer margin strength from procurement timing: Advance procurement of phosphatic/potassic fertilizers ahead of Kharif enabled the complex fertilizer segment to deliver strong margins and an EBIT surge despite subsidy rate lags and cost inflation. The approach will moderate as inventories average but retains a structural edge.
- Shift toward higher-margin specialty agri-inputs: Crop protection, seeds, and biologicals businesses are improving profitability through new product launches and better mix, while the TERI partnership promises next-generation sustainable agri solutions for future export potential, reinforcing the non-subsidy earnings stream.
- Government subsidy engagement and policy delays: Kharif NBS rates were raised ~10% but do not reflect post-announcement input cost spikes; industry is in discussions for relief. Management interprets government's delay as a fiscal balancing act, with potential action by October.
- Capital allocation discipline: Management commits to maintaining dividends (~25% payout) despite large impending capex; buyback is off the table unless project visibility disappears, signaling a clear growth-over-shareholder-return priority.
Operational commentary
- Government approved National Investment Policy for Urea 2026; Chambal progressing preparatory activities for a fourth urea plant at Gadepan, investment decision subject to Board approval.
- TAN project: production commenced of Weak Nitric Acid and Ammonium Nitrate solutions; high-density Ammonium Nitrate (HDAN) closer to commissioning; all product/marketing elements targeted for completion by Dec-26.
- Complex fertilizer business benefited from advance procurement of phosphatic/potassic fertilizers ahead of Kharif, supporting strong segment EBIT and margins; introduced ammonium sulphate grade and evaluating newer NPK grades.
- Crop protection and specialty business launched seven new products (herbicides, fungicides, insecticides); margins improved via better product mix; seeds business added two maize and bajra varieties.
- Biologicals business: volume/revenue growth and profitability driven by scale and mix; partnered with TERI for advanced sustainable agri solutions; dedicated lab operational, products expected from FY28-29.
- Urea sales volumes: Gadepan-1 96k tons, Gadepan-2 1.85 lakh tons, Gadepan-3 3.29 lakh tons; G3 remained the dominant contributor with favorable currency movement boosting segment profitability.
- IMACID JV temporarily shut down due to Sulphur shortages/elevated prices; production resumed in July; expects normalization and improved performance going forward.
- Sourced 8.5 lakh tons of NPK material tied-up with vendors for the year; well-positioned for Rabi placement.
- Monsoon: despite 23% YoY lower sowing in June, July rainfall revival accelerated acreage; management expects strong Q2 demand and channel liquidation driving second round of fertilizer offtake.
Analyst Q&A
Q. Hypothetically, if existing G1/G2 urea plants under NIP-2012 were classified under an older group of NUP-2015, what would be the financial impact?
This is a hypothetical question for which no answer can be given. The plant has not fully depreciated, only eight years into production, and even as per government's old policies the timeline for full depreciation is 15 years. There is no way you can mix the two policies.
Q. With the new urea policy appearing ROE-dilutive relative to NUP-2012, why is it still attractive; what are the scale and synergy benefits?
Advantages of scale at a single site—fixed costs, manpower, optimization of facilities—are tremendous; the spread of our dealer network and cross-sell opportunities are also significant. We believe we have a good investment case, especially if we optimize capital cost.
Q. For the TAN project, does the earlier expectation of 70-80% utilization in FY27 still hold?
The market has responded well to quality, delivery schedules, and pricing; despite a lean season we are confident. HDAN nearing start gives us three products to run in the most profitable combination, and the marketing mix will be completed by December, giving confidence in volumes.
Research and educational content only. Not investment advice.